SBTX Skinbiotherapeutics

EQS-News: SkinBioTherapeutics will 'continue to be flexible enough to adapt to opportunities'

EQS-News: SkinBioTherapeutics PLC
SkinBioTherapeutics will 'continue to be flexible enough to adapt to opportunities'

19.12.2022 / 12:14 CET/CEST
The issuer is solely responsible for the content of this announcement.


Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct


19.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: SkinBioTherapeutics PLC
United States
ISIN: GB00BF33H870
EQS News ID: 1516547

 
End of News EQS News Service

1516547  19.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1516547&application_name=news&site_id=research_pool
EN
19/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Skinbiotherapeutics

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 26/03/2025

Our daily digest of news from UK Small Caps @HybridanLLP 26th March 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None Yester...

Brian Moretta ... (+3)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...

Martin Hall
  • Martin Hall

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...

Hybridan Small Cap Feast - 02 August 24

2nd August 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: Delistings: Lok’nStore Group (LOK.L) has delisted from AIM Tyman (TYMN.L) has delisted from the Premium segment of the Main Market What’s baking in the oven? ** Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email...

Hybridan Small Cap Feast - 29 July 2024

29th July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: Delistings: Nightcap (NIGHT.L) has left AIM R&Q Insurance Holdings (RQIH.L) has left AIM What’s baking in the oven? ** Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email with “unsubscribe me”. Hybridan Chefs ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch